---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Humanistic burden and health-related quality of life. Topics: Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries; Health utilities and medical care use compared with the general population; Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics; Life domains affected in U.S. patients and caregivers; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries

> “Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.”
> “Baseline results of 841 participants (mean age 47 years, 70% women) are reported.”
> “The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.”
> “Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.”
> “MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.”

Source: [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/)

<a id="topic-2.2.1.8.1-2"></a>

### Health utilities and medical care use compared with the general population

> “In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).”
> “Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.1-3"></a>

### Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics

> “Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).”
> “Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.”
> “Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.”

Source: [Pesa et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/43001852/)

<a id="topic-2.2.1.8.1-4"></a>

### Life domains affected in U.S. patients and caregivers

> “across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)”
> “Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).”
> “The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.”
> “Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.”

Source: [Narayanaswami et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400517/)

<a id="topic-2.2.1.8.1-5"></a>

### Systematic review of psychological symptoms and health-related quality of life

> “Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.”
> “However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.”

Source: [Gelinas et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35486970/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
